Annual Report 2012 - 2013
Cancer Research Wales - the people of Wales’ charity. Cancer Research Wales – All money raised is spent in Wales 1 Board of Trustees and O cials Registered Charity No. Shop Support 248767 (1966) Mr Berian Richards Registered O ce Mr Roger Smith Cancer Research Wales Patrons Velindre Cancer Centre Jamie Baulch Velindre Road Huw Edwards Whitchurch Richard Elis Cardi Tonya Smith CF14 2TL Nigel Walker Telephones CRW Chair of Clinical Oncology Fundraising O ce 029 2031 6976 Professor Malcolm Mason Registered O ce 029 2031 6283 Board of Trustees Fax 029 2031 6927 Professor John L. Moore (President) Email Dr John Pritchard C.B.E (Chairman) [email protected] Dr Malcolm Adams Web (Chairman of Scienti c & Research Committee) www.cancerresearchwales.co.uk Mrs Mary Andrews Charity Director Dr Colin S. Askill resigned October 2012 Miss Liz Andrews Mr Michael A.C. Brooke resigned October 2012 Deputy Charity Director Mr R Nevil Davies Mrs Coleen Watkins Dr Chris C. Ga ney Professor Bharat Jasani Scienti c Projects Manager Mr Peter J. Keneally Dr Lee Campbell Mr Gavin Moore Commercial Manager Mrs Gill Owens Mrs Pamela Perkins Mrs Beryl Rees Fundraising Manager Mr Bryn Roberts Miss Laura Hooper (Fundraising Committee Chairman) Fundraiser resigned May 2013 Mrs Wendy Collie Mr Je rey R. Thomas F.C.A A.T.T.I. Financial Administrator (Hon Treasurer) Mrs Gillian Hall Mr Peter Weber (Hon Legal Advisor) Finance/Administration Assistants Auditors Mrs Sharon Bonetto Watts Gregory LLP Miss Ruth Davies Elfed House Legacy O cer Oak Tree Court Mrs Helen Je reys Mulberry Drive Shop Managers Cardi Gate Business Park Ms Sarah Callow Cardi CF23 8RS Mrs Karen O’Brien Bankers Mrs Julia Simon Unity Trust Bank CAF Bank Ms Stephanie Tanner Nine Brindley Place PO Box 289 Mrs Deborah Drew Birmingham B1 2HB West Malling Kent ME19 4TA i Cancer Research Wales – All money raised is spent in Wales Chairman’s Message
The current economic situation remains di cult for many people, but it is important to highlight that the support for Cancer Research Wales continues to grow. This enables the charity to fund an increasing number of highly rated peer reviewed research projects. Examples of the diverse nature of the research are contained in this report. The CRW Symposium held in March 2013 with the theme, ‘Towards Personalised Cancer Treatment’, hosted by Sian Lloyd was a huge success. This was an opportunity for such as walking the perimeter of Wales. scientists, funded by CRW, to discuss their These examples serve to show the huge projects and results, with an audience of commitment and e ort to raise money for varied backgrounds. The Symposium also CRW. We are very grateful for the enormous provided a platform for an announcement support the charity receives enabling us to that £1.5m would be made available for an allocate an additional £1m of new monies for important new project, ‘Strati ed Medicine’, research projects in Wales. over the coming years. This project will aim to ensure that future cancer patients receive the I am sure that the demands to fund new most appropriate treatment for their cancer research will continue to grow. All requests for through targeted therapy; demonstrating funding will remain to be peer reviewed by CRW’s commitment to improving patient care external experts, ensuring that monies raised and outcome as a result of research. are spent on the best projects in Wales. The continued ability to fund new research Please continue to help us, through excellent activities by CRW is only possible because research, to improve treatment outcome and of the huge support by the people and quality of life in cancer care for patients in organisations of Wales; individually and Wales. corporately. For example the Principality Building Society’s Charity of the Year which raised £72,226; and the Farmers Union of Wales which raised £50,000. Furthermore the carrier bag scheme, supported by independent retailers and larger organisations, such as Poundland which raised £32,804 and individual activities Dr John Pritchard CBE
Cancer Research Wales – All money raised is spent in Wales 3 Contents
i Board of Trustees and O cials 1 Chairman’s Message 3 Overview of Research - Professor M Mason 4 Overview of Cancer Research Wales Scienti c Programme - Dr Malcolm Adams 5 Titles and Authors of Funded Projects 15 Cancer Research Wales Library 16 Fundraising Activities 21 Acknowledgements 40 Independent Auditors Report to the Trustees of Cancer Research Wales 42 Statement of Financial Activities 43 Balance Sheet 44 Summary: Income & Expenditure
4 Cancer Research Wales – All money raised is spent in Wales Overview of Research that the work undertaken on the programme grant will result in a better understanding of these processes and lead to the optimal use of these agents, in addition to the discovery of new drug targets. In the forthcoming year the Wales Cancer Bank will reach two very important milestones, namely, its 10th anniversary and the consenting of its 10,000th patient. To date over 60 di erent projects in the U.K and Europe have been approved samples as part of their studies. The promise of delivering personalised medicine for the treatment of cancer has not come without signi cant challenges. We now understand how single tumours and their associated metastatic lesions evolve to develop di erent As Cancer Research Wales’ Chair of Clinical mutations during the course of the disease, Oncology, it has been a thrill to see the changes that may limit the use of single incredible strides that the charity has made agents developed to target speci c genetic over the last few years. The breadth and depth defects. The Wales Cancer Bank is strategically of talent we have in Wales and the exciting positioned to tackle these important issues research that is taking place was clearly and help decipher the correct sequencing evident at the one-day science symposium or combination of these newer or indeed hosted by Cancer Research Wales in March conventional treatments, allowing the best for 2013. Many di erent topics were covered patients. A grant recently awarded by Cancer during the day which brought together Research Wales for the full characterisation of people from all backgrounds including cancer tumours will help achieve this goal. scientists, clinicians, radiologists and cancer Our profound thanks go to all the patients research nurses, highlighting just how and their families who kindly donated multidisciplinary cancer treatment and care samples, and the various NHS organisations has become. across Wales, who together make this The Cancer Research Wales programme grant ambitious project a success. We are continues to go from strength to strength, continually amazed and extremely grateful for with several of the scientists involved on the all the wonderful work our loyal supporters project receiving awards and recognition at continue to do for Cancer Research Wales, international conferences and workshops. even during the midst of a di cult economic The focus of this research is to understand the climate. This support helps toward achieving complex interplay that occurs between the our goal of reducing the impact of cancer on immune system and prostate cancer cells and the people of Wales through the funding of how this can lead to aggressive disease. This world class cancer research and education. work is very relevant since a number of new Professor Malcolm Mason drugs which seek to harness the power of the Cancer Research Wales immune system are currently being tested Chair of Clinical Oncology for metastatic prostate cancer. It is hoped Cardi University Cancer Research Wales – All money raised is spent in Wales 5 Overview of Cancer Research Wales Scienti c Programme It was inspiring to see new projects added to the Cancer Research Wales research portfolio dealing with unmet clinical needs in myeloid leukaemia and ovarian cancer. Looking ahead we are pleased to launch a new scholarship in brain tumour research in memory of Mr Ed Evans who tirelessly raised funds for Cancer Research Wales until his sad death in 2007. Professor Malcolm Mason who holds the Cancer Research Wales Chair of Clinical Oncology, was honoured with the prestigious William Farr medal. This is awarded annually to medical practitioners who have made a signi cant contribution to the treatment of elderly patients through original research It has been another excellent year for Cancer conducted in the U.K. Professor Mason received Research Wales, which culminated in our the award in recognition of the pioneering second Scienti c Symposium held at the and practice changing clinical trials he helped SWALEC Stadium, Cardi , in March 2013 and lead in the eld of prostate cancer, trials which opened by the Health Minister, Ms Lesley improved survival by 8-10%. Gri ths. The event brought together some We are proud to invest in the future of Wales’ renowned cancer scientists and generations of cancer researchers in Wales clinicians providing an ideal forum to share and as a result currently fund a total of 30 results, ideas and form new collaborations. We PhD students and 9 post-doctoral scientists. very much look forward to staging the next Therefore, it gives me immense pleasure to say one in 2016 to mark the 50th anniversary of a big thank you to all our wonderful supporters the charity. who generously give both their time and The tremendous support we continue to money. Please browse through the abstracts receive from the public has meant that of the ground breaking research funded by Cancer Research Wales continues to grow. Cancer Research Wales. Work that is hoped will This year saw a grant awarded to the Wales make a real di erence to cancer patients and Cancer Bank, allowing the full molecular their families and which could not take place characterisation of thousands of individual without your support. tumours within the collection. This will provide an invaluable resource for scientists as the move toward personalised cancer medicine gains momentum. Another important initiative we were able to support was module 4 of the International Cancer Benchmarking Partnership which seeks to nd the causes of Dr Malcolm Adams delays in diagnosis and treatment in cancer Chairman of Scienti c & Research patients across Wales. Committee
6 Cancer Research Wales – All money raised is spent in Wales Funded Projects The Wales Cancer Bank Malcolm Mason, Gerry Thomas and Alison Parry-Jones Institute of Cancer and Genetics, School of Medicine, Cardi University, Velindre Cancer Centre, Cardi The Wales Cancer Bank (WCB) collects blood, serum and frozen and para n embedded tissue from patients undergoing treatment for cancer in Wales. Established in 2004, the WCB has since consented over 9,200 patients. The current collection includes 23 tissue sites, the largest collections being breast, colorectal, prostate, bladder and renal. Data is linked-anonymised via the all-Wales electronic clinical database (CanISC), and consent permits future access to clinical outcome data. Molecular characterisation of thousands of individual tumours is currently ongoing and when complete will represent an invaluable resource for scientists for many years to come. These studies will in future help clinicians make better informed decisions with respect to prognosis and prediction of treatment response. WCB is licensed by the Human Tissue Authority and approved by NRES as a Research Tissue Bank. WCB has received applications from research projects in the UK, Europe, Canada and S. Korea. Clinical Trials Unit Eve-Gallop Evans, Velindre NHS Trust, Cardi At Velindre Cancer Centre, clinical trials are seen as an integral part of high quality cancer care. We have been treating increasing numbers of patients since the Clinical Trials Unit opened in 1994, and are grateful for generous support from CRW. We have more than 60 open trials including phase 1 trials of new cancer drugs being tested in humans for the rst time, given in the brand new Clinical Research Treatment Unit. CRW support of local research projects also provides our clinical and research sta with opportunities to lead practice changing research which can then be tested in clinical trials, and ultimately improve patient care. Using Next Generation Sequencing to Study the Genetics and Pharmacogenetics of Colorectal Cancer Marc Naven, Chris Smith, Jeremy Cheadle and Kevin Ashelford Institute of Cancer and Genetics, School of Medicine, Cardi University Gene variations in the DNA of individuals can make some people more susceptible to certain cancers than others. In this project we have developed and tested a computer-based pipeline for detecting and storing gene variant information (variant calling) from the advanced next generation sequencing of high-quality blood DNA. We are now using this pipeline to determine the feasibility of variant calling from DNA extracted from processed tumour samples, which can su er from poor quality DNA as a result of tissue processing. We have found that although the technology worked better for DNA from blood than from tumour DNA, both were adequate for variant calling. We are trying to develop robust protocols that can be put in place for sequencing tumour samples. In future this may help with the detection of cancer susceptibility genes that could be used for screening purposes in colorectal cancer. Cancer Research Wales – All money raised is spent in Wales 7 Elucidating the Role of Regulatory T Cells in Colorectal Cancer Progression Matthieu Besnuex, Awen Gallimore and Andrew Godkin Dept. of Infection and Immunity, School of Medicine, Cardi University, Cardi There is a pressing need for new treatments for colorectal cancer (CRC). Within the immune system, there is a small population of white cells known as Tregs, which actively suppress e ective immune responses to CRC. The overarching objective of this study is to determine how Tregs can be distinguished from useful white cells (ones that kill tumours) in order that we can selectively interfere with their function as a method of promoting e ective anti-cancer immune responses. The information Dr Andrew Godkin obtained thus far is directly relevant to improving the design of immune-modulating strategies to improve the e ectiveness of vaccines that are being used for the treatment of advanced colorectal cancer. The Role of Brachyury in Colorectal Cancer Jana Jezkova and Jane Wakeman North West Cancer Research Fund Institute Dept. of Biological Sciences, Bangor University Treatment of cancers is complicated because not all cells in a tumour are the same. Long-term successful treatment of colorectal cancer will depend on speci c elimination of a group of cells within the tumour that can evade standard therapeutic treatments. After therapy, these cancer cells can lie dormant and then over time, can become ‘activated’ to form a new tumour. Work carried out in our lab has recently shown that a factor known as Brachyury is important in allowing cancer cells to ‘lie’ in a ‘dormant’ state and so may be important in allowing evasion of tumour cells to therapeutic agents. Identi cation of Novel Targets for Immunotherapy of Colorectal Cancer Martin Scurr, Kathryn Smart, H Batha, Mike Davies, Simon Phillips, Rachel Hargest, Gareth Williams, Adam Christian, Tom Hockey, Awen Gallimore and Andrew Godkin Depts. of Infection and Immunity, Surgery, and Histopathology, School of Medicine, Cardi University, Cardi Cancers progress due to the immune system’s failure to adequately arrest and eradicate growing tumours. One reason, is the ability of immunosuppressive regulatory T cells to inactivate bene cial T e ector cells which function to remove malignant cells. We have recently identi ed a new type of regulatory T cell in patients with colon cancer, which is 100 times more potent in its ability to suppress anti-tumour immune responses. These cells express unique molecules known as LAG-3 and LAP that may be targeted as a novel therapeutic strategy for advanced colon cancer. Elsewhere, we have revealed that the loss of recognition of immune cells to 5T4 (a molecule that is expressed on the outside of colon cancer cells) is an accurate pre-operative indicator of early relapse with metastatic disease. Both these existing avenues will form the basis of future research. 8 Cancer Research Wales – All money raised is spent in Wales Identi cation of Molecular Determinants of Cancer Stem Cells Vicente Planells Palop, Ramsay McFarlane and Jane Wakeman North West Cancer Research Fund Institute Dept. of Biological Sciences, Bangor University Cancer Stem Cells (CSCs) are believed to be responsible for local relapse and metastasis of tumours and may also be the cells that are responsible for resistance to therapies. As such, it is of fundamental importance to study the molecular mechanisms which enable certain genes to induce properties of CSCs. Studies in our lab suggest that a factor normally associated with the early development of embryo’s may be involved in changing a normal cell to a cancer stem cell, thereby making it a potential therapeutic target. Caveolin-1 is a Key Determinant of the Stem-like Characteristics of Renal Cell Carcinoma Robert Gutteridge, Mathew Smith, Chris Pepper, David Gri ths and Mark Gumbleton Experimental Cancer Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Cardi University, Institute of Cancer Genetics and Department of Cellular Pathology, School of Medicine, Cardi University Renal cell carcinoma (RCC) is a cancer characterised by aggressive features such as a high rate of metastasis (the ability for cancer to spread), chemo/radiotherapeutic resistance and disease recurrence after initial treatment. In recent years, a population of cells has been identi ed in solid tumours that are thought to be responsible for these aggressive features as well as driving the growth of tumours. Such populations of cells have been termed cancer stem cells (CSC). Previously, in patient tissue samples, we have shown that levels of the protein caveolin-1 associate strongly with the aggressive disease characteristics of RCC. In this project we are seeking to examine the function of caveolin-1 in CSC populations of RCC samples and evaluate its potential as a target for drug intervention by direct modulation of CSC behaviour. Targeting Bone Metastasis in Prostate and Breast Cancer Sioned Owen, Andrew Sanders, Anna Sobkowisz, Lin Ye, Malcolm Mason and Wen Jiang Metastasis and Angiogenesis Research Group, School of Medicine, Cardi University, Heath Park, Cardi Breast and prostate cancer are two of the most commonly diagnosed cancers amongst men and women in the UK. Both these cancers have been shown to preferentially metastasise to the bone. This diagnosis often occurs in advanced and relapsed stages of the disease, sometimes after long periods of remittance. Currently there is a lack of tests to identify those most at risk and monitor potential metastatic sites. Our current study is examining how breast and prostate cancer progression to the bone is a ected by molecules that regulate bone turnover. Targeting these molecules could in the future provide a strategy to provide better prognostic markers for bone metastasis.
Cancer Research Wales – All money raised is spent in Wales 9 FAK as a Novel Therapeutic Target in Breast Cancer Glorianne Lazaro, Peter Barrett-Lee and Stephen Hiscox School of Pharmacy and Pharmaceutical Sciences, Cardi University, Velindre Cancer Centre, Cardi Focal adhesion kinase (FAK) is a protein that plays an important role in the growth and movement of normal cells. Our research has shown that HER2+ breast cancer cells have high levels of FAK which, when inhibited, can enhance their sensitivity to the drug, Herceptin. Excitingly, we have also discovered that HER2+ breast cancer cells can be instructed to move around by other cell types commonly found in tumours and that breast cancer FAK is a key part of this process. This suggests that by preventing FAK from functioning in HER2+ breast cancer, we may also reduce the capacity of breast cancer cells to spread. Dr Steve Hiscox Inducing Tyrosine Receptor Degradation as a Novel Therapeutic Strategy in Breast Cancer Helen Wiggins, Steve Hiscox, Andrew Westwell and Arwyn Jones School of Pharmacy and Pharmaceutical Sciences, Cardi University Annually in the UK, breast cancer accounts for over 10,000 deaths, thus novel therapeutic strategies are needed to target this disease. We have been investigating the anti-breast cancer properties of a drug called disul ram, and other compounds with structural similarities. Our studies suggest that disul ram is able to kill breast cancer cells that are dependent on oestrogen for growth, whilst leaving non-cancerous breast cells and non- oestrogen dependent cells unharmed. We are also investigating how some metal ions such as zinc and copper may alter disul ram’s anti-breast cancer properties. This raises the hope that disul ram may be used in conjunction with other anti-cancer agents to improve breast cancer prognosis. Design and Synthesis of Molecular Inhibitors of c-FLIP Activity as a Therapeutic Strategy to Target Breast Cancer Stem Cells Olivia Hayward, Richard Clarkson, Andrea Brancale and Andrew Westwell European Cancer Stem Cell Research Institute and School of Pharmacy and Pharmaceutical Sciences, Cardi University This study aims to develop a chemical inhibitor of c-FLIP, a naturally occurring factor responsible for the resistance of breast tumours to anti-cancer drugs. State-of-the-art computer software used ‘virtual’ chemical compounds to inhibit a computer-generated c-FLIP molecules. This led to the identi cation of 10 candidate compounds, which were synthesised and tested on breast cancer cells in the laboratory. Two of these compounds inhibited c-FLIP activity. The student is collaborating with European laboratories to develop a technique to study exactly how the new chemical agents inhibit c-FLIP within tumour cells. 10 Cancer Research Wales – All money raised is spent in Wales ADAM15-Mediated Remodelling of the Actin Cytoskeleton in Breast Cancer Cells Zaruhi Poghosyan and Vera Knauper Cancer and Genetics Institute, School of Medicine and School of Dentistry, Cardi University We have discovered that the protein ADAM15 exists in several alternative forms, and when some of these forms are present in breast tumours, these patients have shorter survival. We have shown that the various ADAM15 forms are able to a ect the shape of breast cancer cells in di erent ways, including their ability to move and invade. This project aims to understand how ADAM15 variants interact with other cancer promoting proteins such as Src and Brk, and how these interactions a ect the shape of breast cancer cells and change their ability to move. This study will help us to understand why some breast tumours are more aggressive than others. High Resolution Dosimetry in Small-Field and Intensity-Modulated Radiotherapy Maria Piliero, Richard Hugtenburg and Simon Ryde School of Medicine, Swansea University, Department of Medical Physics and Clinical Engineering, Abertawe Bro Morgannwg UHB Radiation dosimeters made from synthetic diamond have been developed and can improve some radiotherapy treatments. Prototypes provided by Diamond Detectors Ltd were tested, and following several iterations of design, were shown to be acceptable for use in small- eld radiotherapy dosimetry. The testing considered the sensitivity and stability of the dosimeters, including their performance in a clinical context; small radiation elds and large variations in the rate at which the radiation is delivered are now a standard feature of intensity-modulated therapy. Analysis of the behaviour of the dosimeters at very short time-scales has led to improvements in the theory describing their performance, which it is hoped will translate into more accurate targeting of tumours during radiotherapy treatment. A Comparison of Superposition/Convolution and Monte Carlo Methods for Radiotherapy Dewi Johns and Geraint Lewis Dept. of Medical Physics, Velindre Cancer Centre, Cardi Most radiotherapy is delivered by linear accelerators, machines that deliver a shaped radiation beam to the cancer patient from any direction. Specialist software, called a Treatment Planning System (TPS), is used to determine the best arrangement of radiation beams to treat the patient. The TPS calculates the radiation dose deposited in the patient from the proposed beam arrangement, and displays the result, allowing the user to adapt and improve the dose distribution. This project will compare the two most common calculation methods with the gold standard, for large numbers of cases to establish the e ect of choice of calculation type on the dose distribution calculated.
Cancer Research Wales – All money raised is spent in Wales 11 Positron Emission Tomography-Based Target Volume Delineation for Radiation Treatment Planning in Head & Neck Cancers Bertrice Berthon, Chris Marshall, Mererid Evans and Emilliano Spezi Wales Research & Diagnostic Positron Emission Tomography Imaging Centre, School of Medicine, Cardi University; Department of Medical Physics, Velindre Cancer Centre, Cardi 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG - PET) has the potential to improve Radiotherapy Treatment (RT) planning by highlighting metabolically active cancer cells. A major challenge for the use of FDG – PET in Radiation Therapy is the accurate demarcation of the target lesion, which is hampered by the poor resolution of PET-images. The project aims at investigating the performance of advanced PET automatic segmentation (PET- AS) methods, and developing an optimised PET-AS tool for Head and Neck (H&N) segmentation that can be used in the RT planning process. We have developed, validated and compared eight methods and the best performing methods are being applied to oropharyngeal patients, a type of H&N cancer. These patients are scanned at the Wales Research & Diagnostic Positron Emission Tomography Imaging Centre, and then undergo Radiotherapy Treatment at Velindre Cancer Centre in Cardi . Synthetic Routes to 18F-Labelled Gemcitabine and Related 2’-Fluoronucleosides Jan-Philip Meyer, Chris McGuigan, and Andrew Westwell School of Pharmacy and Pharmaceutical Sciences, Cardi University A major challenge for Positron Emission Tomography (PET) research is the development of e cient chemical methods for preparation of PET tracer molecules or cancer drugs for patient administration. In this project we have been developing methods towards the PET-labelling (18F) of the anti-cancer drug Gemcitabine (Gemzari(TM)), which is used as rst line therapy for pancreatic cancer, and is also clinically approved for treatment of other solid tumours such as lung, breast and bladder cancer. Despite its approved drug status, Gemcitabine su ers from poor and variable tumour uptake and metabolism. Having a PET radiolabelled version of the drug would be a major milestone in the eld, assisting the future development of superior therapeutics in these di cult disease areas. DNA Methylation as a Triage Test to Augment Human Papillomavirus Testing in Cervical Screening Dean Bryant, Sam Hibbits, Amanda Tristram, Alison Fiander and Ned Powell HPV Research Group, Dept. of Obstetrics and Gynaecology, School of Medicine, Cardi University Cervical cancer is caused by persistent infection with Human Papillomavirus (HPV). The current cervical screening programme could be improved by testing for HPV related biomarkers. DNA methylation is a chemical modi cation found on both HPV and human DNA. In a normal 12 Cancer Research Wales – All money raised is spent in Wales screening population, we previously found that more severe cervical disease had more highly methylated HPV DNA. Measurement of HPV DNA methylation has since been proposed as a test to identify patients at risk of developing cervical cancer. However, our current study found that these methylation di erences were not present in younger women. Our ndings suggest that tests suitable for identifying disease in older women may not be appropriate for younger women. Genome-wide Analysis of Topoisomerase Removal After Camptothecin Treatment in The Context of Replication and Transcription Karim Garrido, Shirong Yu, Mark Bennet, James Powell, Simon Reed and Edgar Hartsuiker North West Cancer Research Fund Institute School of Biological Sciences, Bangor University; Institute of Cancer and Genetics, School of Medicine, Cardi University Many cancer treatments used in the clinic kill cancer cells by damaging their DNA. Topoisomerase inhibitors kill cancer cells by strongly locking a protein, called topoisomerase, onto the DNA. For a cancer cell to survive treatment, it needs to remove this protein. The aim of this proposal is to study genome-wide DNA repair mechanisms that remove topoisomerase from DNA. We have now successfully established a methodology to study the genome- wide distribution of DNA bound Topoisomerase. The proposed research will increase our understanding of the mechanisms that help cancer cells survive treatment with topoisomerase inhibitors. The long term view of the study is to access the suitability of genes involved in topoisomerase removal as prognostic markers and drug targets in order to improve outcome in patients treated with these classes of drugs. South Wales Human Papillomavirus (HPV) Prevalence in Oropharyngeal Cancer Study Mererid Evans, Robert Newcombe, Alison Fiander, James Powell, Martin Rolles, Selvam Thavaraj, Max Robinson and Ned Powell HPV Research Group, Depts. of Obstetrics and Gynaecology, Primary Care, School of Medicine, Cardi University, Singleton Hospital, Swansea, Velindre Cancer Centre, Cardi and other collaborating centres The incidence of oropharyngeal cancer (OPC), involving the tonsils and tongue base, is increasing faster than any other tumour type in the UK. Human Papillomavirus (HPV) testing was performed on 138 cases of oropharyngeal cancer diagnosed in South Wales between 2001-2006. HPV was detected in 55% of cases. Five year overall survival was signi cantly better in patients with HPV-positive cancers Dr Mererid Evans (75%), compared to those with HPV-negative cancers (25%). Ongoing work con rms a further rise in the proportion of HPV-positive OPC across South Wales. The results support routine testing of OPC for HPV and future HPV vaccination of boys. Cancer Research Wales – All money raised is spent in Wales 13 T-cell Receptors for Cancer Immunotherapy Valentina Bianchi, David Cole and Andrew Sewell Dept. of Infection and Immunity, School of Medicine, Cardi University, Cardi There is increasing interest in new immunotherapies which exploit the body’s own immune system to ght cancer. We are dissecting successful immune responses to malignant melanoma, an aggressive form of skin cancer, in cases where the cancer has spread to other parts of the body. We have already established killer T-cells (a highly specialised form of immune cell) from these patients that kill cancer cells. Our aim is to understand how these patients have cleared their cancer in the hope that we can then transfer this remarkable success to other patients and other cancers. Immune Cells in the Tumour are Activated by Dying Cancer Cells Josephine Salimu, Saly Al-Taei, Lisa Spary, Malcolm Mason, John Sta urth and Zsuzsanna Tabi Cancer Research Wales Laboratories, Velindre Cancer Centre, Institute of Cancer & Genetics, School of Medicine, Cardi University Dendritic cells (DC) are specialised immune cells which are able to sense signals that are dangerous for the organism and initiate an immune response. We have shown that irradiated tumour cells are taken up (or “eaten”) by DC which then activate other e ector immune cells or T cells. T cells can cause further damage to cancer cells. We recently revealed that DC can carry out the above function without further activation and can generate an immune stimulatory environment. Soluble factors produced by DC, after taking up irradiated tumour cells (IL-12, CXCL10), are able to attract and activate e ector T cells. Corruption of Monocytes in the Tumour Tissue by Stromal Cells Lisa Spary, Malcolm Mason and Zsuzsanna Tabi Cancer Research Wales Laboratories, Velindre Cancer Centre, Institute of Cancer & Genetics, School of Medicine, Cardi University For prostate cancer development tumour cells require a network of support from the surrounding cells, known as tumour stroma. We are studying the e ects that tumour stroma can have on immune cells. We found that monocytes, a type of immune cell, preferentially migrate towards tumour stroma. Exposure of these monocytes to soluble factors produced by the tumour stroma alters their development and can be characterised by the presence of molecules that can inhibit the immune response. These inhibitory molecules, known as PD-L1 and CD200R, can prevent the activation of other immune cells known as T cells. While ongoing clinical trials are already targeting these inhibitory molecules, our results will help in understanding why these molecules appear on immune cells in cancer and how we can prevent this process to further improve immunotherapy.
14 Cancer Research Wales – All money raised is spent in Wales Radiation Treatment Alters Soluble Factor Production by Tumour Stroma Lisa Spary, Malcolm Mason and Zsuzsanna Tabi Cancer Research Wales Laboratories, Velindre Cancer Centre, Institute of Cancer & Genetics, School of Medicine, Cardi University Radiation therapy is one of the main treatments of cancer. While radiation has a well characterised e ect of damaging and destroying tumour cells, we know relatively little about its e ect on other cells, namely on stromal cells which provide support for the cancer cells. We embarked on characterising how radiation treatment a ects stromal cells in prostate cancer. Our results indicate that radiation triggers increased production of soluble factors (G-CSF, IL-8) which help the recruitment of immune cells into the tumour tissue. Unlike untreated stroma, radiation creates an immune-stimulatory environment. Ongoing work is focusing on the nature of these immune cells and ways to help their anti-tumour function which can ultimately be used to increase the e ciency of radiotherapy. Role of Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Prostate Cancer Metastasis to the Bone Andrew Sanders, Anna Sobkowicz, Sioned Owen, Lin Ye, Malcolm Mason and Wen Jiang Metastasis and Angiogenesis Research Group, Dept. of Surgery, Institute of Cancer and Genetics, School of Medicine, Cardi University Prostate cancer is one of the most frequently diagnosed male cancers. The spread of prostate cancer, commonly to the bones, is a leading factor in determining patient prognosis and is associated with signi cant patient morbidity and mortality. In our current study we are exploring the importance of Activated Leukocyte Cell Adhesion Molecule (ALCAM) in the spread of cancer to the bone. Targeting of ALCAM in prostate cancer enhanced the aggressive nature of these cells in a bone like environment. Our current data suggests that ALCAM may be important in regulating how cancer Professor Wen Jiang cells act in a bone environment. Role of Paxillin in Prostate Cancer Metastasis Anna Sobkowicz, Andrew Sanders, Sioned Owen, Lin Ye, Malcolm Mason and Wen Jiang Metastasis and Angiogenesis Research Group, Dept. of Surgery, Institute of Cancer and Genetics, School of Medicine, Cardi University Prostate cancer is characterised by its tendency to spread to the bone. The exact reasoning for this predisposition to spread to the bone remains unclear. Paxillin is a protein involved in cellular attachment and therefore may play an important role in the colonisation of new organs. Our current study aims to identify the importance of Paxillin in prostate cancer spread to bone and the responsiveness of prostate cancer cells to Hepatocyte Growth Factor (HGF), a key growth factor linked to cancer spread and aggression. Cancer Research Wales – All money raised is spent in Wales 15 Prostate Cancer Exosomes Alter the Di erentiation of Mesenchymal Stem Cells Ridwana Chowdhury, Jason Webber, Zsuzsanna Tabi, Malcolm Mason and Aled Clayton Cancer Research Wales Laboratories, Velindre Cancer Centre, Institute of Cancer & Genetics, School of Medicine, Cardi University Mesenchymal stem cells (MSC) have the ability to change into several di erent types of cells. They play a natural role in healing injuries in the body. In cancer, however, they may have unwanted e ects on tumour growth. We stimulated MSC with tiny vesicles (called exosomes) isolated from cancer cells, and have measured a host of signi cant changes. Firstly the MSC changed into a wound-healing like cell (myo broblast). Lastly these cells produced elevated factors that encourage blood vessel formation, and tumour growth. Exosomes are a major regulator of MSC cell fate, and this has implications for disease progression. Protein Changes in Diseased Stroma Jason Webber, Lisa Spary, Zsuzsanna Tabi, Malcolm Mason, Ian Brewis and Aled Clayton Cancer Research Wales Laboratories, Velindre Cancer Centre; Institute of Cancer & Genetics and Institute of Translation, Innovation, Methodology and Engagement (TIME), School of Medicine, Cardi University We have been investigating how cancer cells alter the surrounding normal cells (or stroma), into behaving in a tumour promoting manner. We are using a technological approach called mass-spectrometric proteomics, to identify molecules that can distinguish normal from diseased stroma. We are also comparing di erent means of activating normal cells, and examine how well they change towards the disease cell type. We are able to identify ~300 di erent proteins per analysis, and have an indication of how these are present in di ering amounts across the samples. We are identifying some novel markers of disease- related stroma, and show that we can activate normal stroma to become disease-like using cancer-cell derived factors. Dr Jason Webber The Tumour Stroma in Prostate Cancer: The Role of Cancer Exosomes on Stromal Cells Jason Webber, Lisa Spary, Andrew Sanders, Wen Jiang, Jennifer Wymant, Arwyn Jones, Zsuzsanna Tabi, Malcolm Mason and Aled Clayton Cancer Research Wales Laboratories, Velindre Cancer Centre, Institute of Cancer & Genetics, School of Medicine; School of Pharmacy and Pharmaceutical Science, Cardi University We have studied how tiny vesicles (exosomes) produced by prostate cancer cells can manipulate the cancer tissue, and alter tumour growth. We have shown that exosomes are the major stimulus for altering normal stromal cells surrounding tumours to support blood vessel growth, and to generate faster growing and larger tumours. We therefore identify exosomes as a useful therapeutic target, and interfering with the actions of cancer exosomes will likely slow or halt tumour growth, and be of bene t to cancer patients. We are currently investigating methods of doing this. 16 Cancer Research Wales – All money raised is spent in Wales Cancer Research Wales Library Llyfrgell Ymchwil Canser Cymru The only specialist Cancer Library in Wales Bernadette Coles - Librarian Anne Cleves - Assistant Library Manager Cancer Research Wales funds 95% of the library’s service costs and 50% of our sta costs CRW Library is the primary library service provider for Velindre Cancer Centre as well as serving other divisions of Velindre NHS Trust. The role of the library is to support all members of Velindre NHS Trust sta during the course of their work, continuing professional development and research activities. The library is also one of Cardi University’s site libraries and provides support to sta and students of all health disciplines across Wales.
The support provided by Cancer Research Wales also enables the library to support any health professional in Wales and other Welsh Charities with their cancer information needs.
Over the summer we took the opportunity to ask our users what kind of library they would like to see over the next few years. We ran a survey which was essentially designed to seek opinion on electronic versus print material. The results mean that from 2014 we will be investing in more electronic journal titles but our readers say very rmly that they want their textbooks to be good old fashioned paper!!!
Other highlights have been: • Our librarian was invited to speak at the annual Welsh CILIP [Chartered Institute for Information & Library Professionals] conference in Cardi on the theme of collaborative working across sectors. • We were involved in a Customer Service Excellence accreditation process last year and I am pleased to say that we passed with ying colours. We are now in receipt of an accreditation award from Customer Service Excellence (a UK Government o cial standard) and have the certi cate to prove it!!! • Our librarian attended the 21st Annual Cochrane Colloquium in Quebec City in September where she presented a poster and co-presented a workshop. • We are now o cially part of the Cochrane Prostatic Disease and Urologic Cancers team - although they are based in the USA both Bernadette & Anne are assistant Trials Search Co-ordinators for the group.
http://www.wales.nhs.uk/crwlibrary follow us on Twitter @crwlibrary
Cancer Research Wales – All money raised is spent in Wales 17 The Cancer Research Wales Science Symposium March 2013
In March 2013, Cancer Research Wales clinicians make better informed treatment hosted a Scienti c Symposium at the Swalec choices for individual patients. Stadium in Cardi , an event which attracted During the course of the day many exciting scientists and clinicians from all over Wales. presentations were given describing the The symposium was opened by the Health ground-breaking research that Cancer Minister, Ms Lesley Gri ths, and hosted by Research Wales is able to fund as a result BBC news presenter and journalist, Sian of the wonderful support it receives from Lloyd. This year, the theme was “Toward the public. It also provided an opportunity Personalised Cancer Treatments”. It was tting for many of the Cancer Research Wales that the day was launched in style with the PhD students to give an overview of their announcement of a £1.5M grant made to work and for several, the symposium was the Wales Cancer Bank; for the molecular the rst time they had attended a scienti c characterisation of thousands of tumours conference. The experience they gained on contained within the bank. These studies will the day will prove invaluable as they progress provide an excellent resource for researchers in their studies and careers, where they will for many years to come and in future will help take to the larger international stage. 18 Cancer Research Wales – All money raised is spent in Wales THANK YOU! Cancer Research Wales is proud to be an all Wales charity, guaranteeing that we only fund pioneering cancer research projects here in Wales. We do not receive funding from the government or lottery, and so our work is only possible due to our wonderful supporters and volunteers. Every run, bike ride, cake sale, bucket collection and charity shop sale makes our work possible. So as you challenge yourself to run, walk, climb and organise an event; please remember the hope that you are giving to cancer patients and their families. We are very proud to be the peoples’ charity; YOU make Cancer Research Wales the pioneering charity it is today and YOU make our research projects happen. We wish we could include each supporter and each volunteer within our report, as each and every one of you is very special to us. As you read on, you will see a small insight to the dedication of just some of our inspiring supporters. To all of our volunteers and supporters THANK YOU. You make our work possible.
IRF St Athans 2012 Dave Quarrell Coastal Walk of Wales May 2012
Cancer Research Wales – All money raised is spent in Wales 19 The Cancer Research Our Pink-a-Blue Wales Pink-a-Blue Walks raise funds Walks take place each for our breast and summer in Cardi and prostate cancer Swansea. The Cardi research projects route is 6 miles taking taking place at in Cardi Bay and Welsh hospitals Penarth Marina, with and universities the Swansea walk throughout Wales, taking in 4.5 miles of particularly in Cardi the beautiful Mumbles. and Swansea.
Glamorgan Cricket Team supporting our Pink-a-Blue Walks
This is a fun day out for the whole family, with many of our walkers dressing up! With a fun warm up, face painting and a medal; keep a look out on our website for 2014’s dates. 20 Cancer Research Wales – All money raised is spent in Wales “A massive “thank you” to all of the volunteers and supporters at Cancer Research Wales for the hard work and time you put in for such a great cause. I lost my Grandmother to cancer, so it’s a cause very close to my heart. I have donated a training jacket to Cancer Research Wales and any money it raises will be brilliant. Keep up the great work; those a ected by cancer are very grateful for your ongoing e orts.” Sam Warburton, Cardi Blues, Wales and Lions rugby player “Everyone in some way or another is a ected by cancer. It is a cause very close to my heart. A huge thank you for all the vital support given to Cancer Research Wales, allowing them to continue their fantastic work.” I visited Cancer Research Wales’ laboratories recently and Bethan Witcomb, plays Zoe was in awe of the work they do and their commitment and in Stella passion for the cause. Cancer “It has been an absolute a ects millions of people pleasure to see Cancer including some people very Research Wales grow, close to me, so it’s great to continue to inspire and help see the fantastic work Cancer people in need over the Research Wales are doing in years. It’s a tradition of mine Wales. Without your continued to get my presents wrapped support they wouldn’t be able every year in Cardi ’s city to continue the vital work and centre by the charity’s research needed in ghting wonderful volunteers, and cancer, so thank you. Diolch so may it continue. yn fawr!” Diolch, Matt.” Catrin Stewart, plays Emma in Matt Johnson, TV Presenter Stella and Jenny in Dr Who Cancer Research Wales – All money raised is spent in Wales 21 “The day I was diagnosed with cancer was not one of my best, my whole life changed. It then became a job to spread the word and two things have stood out for me in the two years since ... We all take two things for granted, time and health. I am a proud Welshmen and raising money with the fantastic help of Cancer Research Wales, and knowing that it would be spent on my countrymen, meant so much to me.” Stuart Boddy, Fundraiser
“I started volunteering in 2010 after receiving treatment at Velindre Hospital. I then became aware of Cancer “Rydym yn falch iawn o’r cy e i weithio dros Ymchwil Canser Research Wales and their Cymru yn yr Eisteddfod Genedlaethol. Yn ogystal a chyfarfod ongoing need for volunteers. I a phobl o bob rhan o Gymru a thu hwnt, mae’n gy e i weithio enjoy giving my time as I know gyda gwirfoddolwyr eraill. Pro ad pleserus a gwerthfawr that the money raised is utilised iawn.” within Wales. I also enjoy the “We are very glad of the opportunity to work for Cancer company and friendship of the Research Wales at the National Eisteddfod. In addition to hardworking team based at the meeting people from all parts of Wales and beyond, it is an fundraising o ce. “ opportunity to work with other volunteers. A very pleasurable Mo Burton, Volunteers at and rewarding experience.” our events and helps selling Toni & Dawn Schiavone, Volunteer on the CRW stand at Christmas cards the National Eisteddfod ’I attend the Cancer Research Wales Clothes Sale every year. It’s an annual day out with the girls with beautiful clothes and accessories to be snapped up, as well as lovely gift stalls to browse around. To make it even better whilst having a fantastic day out we are also helping to support Cancer Research Wales, who are doing a fantastic job to help change the lives of those a ected by cancer. I also have many items that I have picked up at a bargain price on my regular trips to their charity shops, it’s far more fun than high street shopping and my money is going to an extremely worthwhile cause where every penny is deserved.’’ Louise Morgan, shops at our charity shops and attends the annual Clothes Sale 22 Cancer Research Wales – All money raised is spent in Wales ‘I get my inspiration from speaking to people when I’m collecting. They tell me their stories and con de in me with their cancer experiences and how they’ve come through it. One lady I spoke to put money in my bucket and she told me she was a cancer su erer and had just six weeks to live. When I collect I think back to that lady and I know that’s why I am there. I get a lot of satisfaction and in my small way I feel I’m making a di erence. I’ve met a lot of friends over the last nine years during my time helping Cancer Research Wales. It’s given me a hobby in life, and I’ve even been awarded an MBE.’ Ken Lawrence, Bucket Collection Volunteer
“I’ve been a volunteer for some years now; helping at bucket collections and events. I enjoy knowing that my help will support groundbreaking research and progress being made by Cancer Research Wales scientists. I love feeling that I’ve made a di erence and meeting generous people.” Roy Robertson, Bucket Collection & Event Volunteer Special Acknowledgements Cancer Research Wales is very grateful for the legacies received in the nancial year 1st April 2012 to 31st March 2013. Legacies have been received from the following Estates: Janet Phyllis Brazell Winifred Muriel Jones Hannah Mary Michael Daniel Davies Mary Marguerite Knight Elizabeth Smith Philip James Dowse Mary Rosamund Lewis Je rey Thomas Diana Mary Francis Winifred Margaret Mackay Clive Price Thomas Rosalind Marjorie Hughes Patricia Mackinnon David Sydney Watkins Cancer Research Wales – All money raised is spent in Wales 23
sea e r c
R h
r W
e
a
c
n l
e
a
s
C
Y
m u r c h m w Cy il Canser
Our Family Bike Ride covers a 16 mile circular route, largely o road, from Whitchurch in Cardi to Cardi Bay. Ideal for families, we nish the bike ride with a BBQ and musical entertainment. Although we can’t guarantee the weather, this summer event does guarantee a great day out for the family! Keep a look out on our website for 2014’s dates. 24 Cancer Research Wales – All money raised is spent in Wales Our annual Golf Day is now in its 17th year; held at Llanishen Golf Club, with gorgeous views across Cardi . A team of 4 can enter for £220, which includes a round of golf, refreshments through the day and a presentation and bu et during the evening.
Cancer Research Wales – All money raised is spent in Wales 25 skydive for FREE
With Cancer Research Wales you can skydive for FREE!! All you need to do is raise a minimum amount in sponsorship, of £395. This covers the cost of the jump, as well as supporting Cancer Research Wales. If you would like the experience of a lifetime then call our fundraising team on 029 2031 6976 for your information pack.
“I skydived in memory of my late father who died of cancer in October 2012. I wanted to raise as much money as possible to help others. People have been so generous because it’s for a good cause. I’m extremely grateful to have had the opportunity of skydiving. Thank you Cancer Research Wales.” Bethan Roberts
26 Cancer Research Wales – All money raised is spent in Wales “I was especially pleased to skydive for this charity because cancer is something which a ects everyone; a patient and their families. It was a wonderful experience and I would recommend it to anybody. As I’m 74 years old, I’ve proved it doesn’t matter how old you are!!” Betty Ellis
“I thought skydiving for Cancer Research Wales would be a great challenge whilst raising money for a good cause. This shocked my family as I am afraid of heights and would not normally get on an aeroplane! The jump itself was very exciting and I wouldn’t think twice before doing it again and would recommend it to anyone. It was a brilliant day and was highlighted by the generosity of the people who sponsored me.” Gethin Davies
Cancer Research Wales – All money raised is spent in Wales 27 Welsh Snowdon 3 Peaks Cader Idris Challenge Pen-Y-Fan
Our supporters have tackled the highest Take in spectacular sights, challenge three peaks in North, Mid and South yourself and accomplish something Wales in just 24 hours! Together with extraordinary! Cancer Research Wales and British Transport, food and instructors are Military Fitness, you too can climb provided, as well as a t shirt and BBQ at Snowdon, Cader Idris and Pen-Y-Fan. the end of the challenge. Also included This is the perfect event if you’re looking in the package is a training day. for an unforgettable experience.
“I have taken part in the Welsh Three Peaks Challenge two years in a row, and I’m looking forward to the third time. The sense of camaraderie on the day is superb, and I have made some lifelong friends. It’s so well organised. All you need to do is enjoy yourself and soak up the amazing scenery! I couldn’t think of a better cause or a better way to raise money for Cancer Research Wales!” Leon Flood
28 Cancer Research Wales – All money raised is spent in Wales If you would like “It’s such an exhilarating feeling when you’re stood on the top of to take part in the peaks. A camera lens just can’t capture the beautiful views; our Welsh Three you really are in awe of the view. It was an experience I’ll never Peaks Challenge, forget, and I recommended it to anyone!” in association Sue Hughes with British Military Fitness then please call us on 029 2031 6976. Our next challenge will take place on Friday 16th - Saturday 17th May 2014.
“Taking part in the 3 peaks with my longest friend really made for lasting memories. What better way to remember my Dad. All of us there on the day were raising money for someone we know or knew, as well as Cancer Research Wales and the hope they bring. The organisation of the event was great, thanks to the hard work behind the scenes by Cancer Research Wales and the boys from the BMF. Thank you to all you guys. Finally what a great view from the top of Snowdon as the sun came up. If you are still thinking about it, don’t, just do it!” Robin Glover
Cancer Research Wales – All money raised is spent in Wales 29 Each Christmas, the Cancer Research Wales team brings festive cheer, as we take away the stresses of Christmas! We wrap your Christmas gifts in return for a donation of your choice. Santa’s little helpers set up at Queens Arcade, Cardi and work right up until Christmas Eve. Our service has raised thousands of pounds, and we are very grateful to all of our volunteers and choirs who help us each year. With special thanks to Queens Arcade, Cardi , International Greetings and Pensord.
“I’ve been a volunteer for various “I’m now in my 5th year “I always use the events with Cancer Research Wales, helping with the Christmas Cancer Research Wales but the Christmas Wrapping Service is Gift Wrapping Service, I love Gift Wrapping Service. my favourite. Myself and two friends working with all the sta I drop o my shopping, enjoy our few hours of fun during and volunteers to raise go for a co ee and the festive season helping with the money for this fantastic come back to it all wrapping and seeing the delight charity. I get to meet done. Twenty quid to on the faces when we hand over fantastic people, have great charity and less hassle the nished parcel. People are very fun - and despite moving for me. What a brilliant generous with their donations, and I away from Cardi two years service!! feel very privileged to be able to help ago, I always come back to Dean Jones, has his with this most worthy charity.” help out.” Christmas presents Virginia Morgan, volunteer at Suzana Piljagic, volunteer wrapped by our Christmas Gift Wrapping at Christmas Gift Wrapping service 30 Cancer Research Wales – All money raised is spent in Wales We’re very fortunate to have the wonderful support of our fundraising committees. Our committees organise many fundraising events throughout the year such as balls, dinners and co ee mornings, raising huge sums of money. We are truly grateful for their support; and consider all of our committees as our extended work force. Ed Evans Foundation
Brecon & Sennybridge Committee
Llanishen Committee Amy Hughes Foundation
Penny Farthing Appeal
Crickhowell Committee
Would you like to get a group together to fundraise on behalf of Cancer Research Wales? We would love to hear from you, and will support you as much as we can. Give us a call on 029 2031 6976. Rita & Roy Johnston Line Dancing Group Cancer Research Wales – All money raised is spent in Wales 31 Pensord
Royal Mint
Peter Alan
Wales Cooperative Centre
During 2012 -2013 we have received wonderful support from the following organisations, a huge thank you to you all! 32 Cancer Research Wales – All money raised is spent in Wales Principality Royal Mint
Amber Energy St David’s Shopping Centre
During 2012 -2013 we have received wonderful support from the following organisations, a huge thank you to you all! Cancer Research Wales – All money raised is spent in Wales 33 Our Bridal Suite o ers brides to be a stunning range of new and pre-owned dresses from some of the wedding industry’s top designers. We also stock a range of bridal shoes, accessories and mother of the bride out ts.
Weddings are times of celebration, happiness and love. Many couples are now choosing to support a charity as part of their special day, often in memory or support of a loved one, or because the charity is special to them or their friends and family.
Bridal Suite 1st Floor Cancer Research Wales Penlline Road Whitchurch Cardi CF14 2AB Tel: 029 2062 7250 34 Cancer Research Wales – All money raised is spent in Wales Cancer Research Wales – All money raised is spent in Wales 35 Dai Green (left), Olympic Athlete.
Cardi University’s Big Band.
Sophie Evans, West End star, and Lucie Jones , X Factor.
36 Cancer Research Wales – All money raised is spent in Wales During October 2012, we were delighted to hold a charity screening of the James Bond lm, Skyfall, a day before general release.
Nigel and Mary Walker.
Cancer Research Wales – All money raised is spent in Wales 37 Carrier Bag Charge 5p As you can see the 5p carrier bag From October 2011 the Welsh Assembly charge really does Government introduced a 5p carrier bag charge generate thousands to all retailers in Wales. The charges are advised to of pounds for us. So be donated to a charitable organisation, and here please ask your local at Cancer Research Wales we are amazed at the shop or take away if they would consider huge sums of money we’re receiving. Small change donating their charge making a big di erence has never been truer. These to Cancer Research 5ps are now in the hundreds of thousands. Wales. For further A special thank you to the following retailers who information please have raised huge amounts for Cancer Research contact us. Wales, by donating their carrier bag charges.
Poundland £32,804.01
One Stop Shop £26,788
We would also like to acknowledge the fantastic support of: Kam Hong Take Away, Pontypridd who have donated a total of £1,781.28 Deri Stores, Rhiwbina who have donated a total of £311.10 38 Cancer Research Wales – All money raised is spent in Wales Ken Lawrence MBE Ken Lawrence aged 85, is a retired milkman from Port Talbot. Each week Ken gives up at least four of his days, dedicating himself to travelling across South Wales and bucket collecting at numerous supermarkets for Cancer Research Wales. We thought Ken deserved a special mention as he has now raised over £200,000 for the charity!! There’s no stopping Ken, and we are so grateful to him for his dedication and support over the years. We were so pleased that in 2011, Ken was awarded with an MBE for his dedication to charity. Thank you so much Ken for all that you do for us here at Cancer Research Wales.
Cancer Research Wales – All money raised is spent in Wales 39 A few more thank yous! Unfortunately we don’t have the space in this report to thank every single supporter or volunteer, but here are a few photographs of our supporters ...
Lois Pugh & friends, Cardi Half Marathon Cardi Male Choir
Eurfyl Lewis & Friends, Jan Adamsons, Lands End to John O’Groats New Years Day swim in Saundersfoot
Beddau RFC, Bike Ride Rhiwbina RFC, Three Legged Race
Aberdare Inner Wheel, Arwel Owen, Llanda Rotary Club, Charity of the Year Trail Marathon Wales Charity of the Year 40 Cancer Research Wales – All money raised is spent in Wales Cancer Research Wales – All money raised is spent in Wales 41 Report of the Independent Auditors to the Trustees of Cancer Research Wales
We have audited the nancial statements of Cancer Research Wales for the year ended 31 March 2013. The nancial reporting framework that has been applied in their preparation is applicable law and the Financial Reporting Standard for Smaller Entities (e ective April 2008) (United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities). This report is made solely to the charity’s trustees, as a body, in accordance with Section 144 of the Charities Act 2011 and regulations made under Section 154 of that Act. Our audit work has been undertaken so that we might state to the charity’s trustees those matters we are required to state to them in an auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.
Respective responsibilities of trustee and auditors As explained more fully in the Statement of Trustees Responsibilities, the trustees are responsible for the preparation of the nancial statements which give a true and fair view. We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with regulations made under Section 154 of that Act. Our responsibility is to audit and express an opinion on the nancial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board’s Ethical Standards for Auditors.
Scope of the audit of the nancial statements An audit involves obtaining evidence about the amounts and disclosures in the nancial statements su cient to give reasonable assurance that the nancial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charity’s circumstances and have been consistently applied and adequately disclosed; the reasonableness of signi cant accounting estimates made by the trustees; and the overall presentation of the nancial statements. In addition, we read all the nancial and non- nancial information in the Report of the Trustees to identify material inconsistencies with the audited nancial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.
42 Cancer Research Wales – All money raised is spent in Wales Opinion on nancial statements Report of the Independent In our opinion the nancial statements: • give a true and fair view of the state of the charity’s a airs as at 31 March 2013 and of its incoming resources and application of resources for the year then ended; Auditors to the Trustees of • have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and Cancer Research Wales • have been prepared in accordance with the requirements of the Charities Act 2011. Matters on which we are required to report by exception We have nothing to report in respect of the following matters where the Charities Act 2011 requires us to report to you if, in our opinion: • the information given in the Report of the Trustees is inconsistent in any material respect with the nancial statements ; or • su cient accounting records have not been kept; or • the nancial statements are not in agreement with the accounting records and returns; or • we have not received all the information and explanations we require for our audit.
Watts Gregory LLP Chartered Accountants & Statutory Auditors Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006 Elfed House Oak Tree Court Cardi Gate Business Park CARDIFF County of Cardi CF23 8RS
Cancer Research Wales – All money raised is spent in Wales 43 Statement of Financial Activities For the year ended 31 March 2013 2013 2012 Unrestricted Total Funds Funds INCOMING RESOURCES £ £ Incoming resources from generated funds Voluntary Income 616,358 1,144,686 Activities for generating funds 1,118,625 884,735 Investment Income 98,693 85,037 Research Projects (Restricted Funds) 15,000 -
Total Incoming Resources 1,848,676 2,114,458
RESOURCES EXPENDED Costs of generating funds Costs of generating voluntary Income 178,906 145,929 Fundraising trading: cost of goods sold and other costs 310,211 266,607 Charitable activities Research projects 2,685,866 2,067,104 Provision of research library 134,536 120,480 Governance Costs 5,782 4,644
Total Resources Expended 3,315,301 2,604,764
NET INCOMING/(OUTGOING) RESOURCES (1,466,625) (490,306)
Other recognised gains/losses Gains/losses on investment assets 241,487 (39,337) Net movements in funds (1,225,138) (529,643)
RECONCILIATION OF FUNDS Total funds brought forward 1,543,094 2,072,737
TOTAL FUNDS CARRIED FORWARD 317,956 1,543,094
44 Cancer Research Wales – All money raised is spent in Wales Balance Sheet For the year ended 31 March 2013 2013 2012 Unrestricted Total Funds Funds FIXED ASSETS £ £ Tangible assets 13,060 15,709 Investments 3,336,606 3,045,721 3,349,666 3,061,430
CURRENT ASSETS Stocks 16,210 25,645 Debtors: amounts falling due within one year 223,957 277,600 Cash at bank 705,665 1,023,974
945,832 1,327,219
CREDITORS Amounts falling due within one year (671,542) (723,200)
NET CURRENT ASSETS 274,290 604,019
TOTAL ASSETS LESS CURRENT LIABILITIES 3,623,956 3,665,449
PROVISIONS FOR LIABILITIES (3,306,000) (2,122,355)
NET ASSETS 317,956 1,543,094
FUNDS Unrestricted funds 302,956 1,543,094 Restricted funds 15,000 -
TOTAL FUNDS 317,956 1,543,094
Cancer Research Wales – All money raised is spent in Wales 45 Summary: Income & Expenditure Year to 31 March 2013
Income FUNDRAISING (33.29%) £610,423 INVESTMENT INCOME & INTEREST (5.38%) £98,693 DONATIONS (18.65%) £342,031 LEGACIES (14.96%) £274,327 CHARITY SHOPS (27.71%) £508,202 TOTAL £1,833,676
Expenditure CHARITABLE OBJECTIVES (85.07%) £2,820,402 GOVERNANCE COSTS (0.17%) £5,782 FUNDRAISING TRADING COSTS (8.13%) £269,531 COSTS OF GENERATING VOLUNTARY INCOME (6.62%) £219,586 TOTAL £3,315,301
46 Cancer Research Wales – All money raised is spent in Wales
Back Cover
MISC
If there are any spare pages, please insert posters for the following: Furniture Collections PHOTO 95 D Day PHOTO 96
(Written by Laura Hooper Nov 2013)